Neuroprotectant agents against oxaliplatin induced neurotoxicity: lackings, facts and future prospective
The recent meta-analysis by Wen et al. [1] aiming to ascertain if Ca/Mg infusion is a valid neuroprotectant against acute and cumulative/chronic oxaliplatin (OXA) neurotoxicity concludes that it might decrease its incidence, without altering the efficacy of chemotherapy. However, this observation is arguable beyond the biases already properly pointed out by the authors.
In fact, a key issue that might reduce strength of their conclusions was not acknowledged: the lack of a gold standard in Chemotherapy-Induced Peripheral Neurotoxicity (CIPN) assessment and, consequently, uncertainty in CIPN incidence and prevalence. This might compromise validity of the protocols designed so far and might introduce an uncontrolled bias particularly in a retrospective literature-based metaanalysis. In particular, all the studies analyzed in the quoted review elected National Cancer Institute-Common Toxicity Criteria to test neurotoxicity, a scale that is known to have yet too many limitations to be chosen as 'the' end-point [2] . In order to overcome this difficulty in CIPN grading, the multicenter, international study CI-PeriNoms, was held [3] . This was the first study so far aimed to determine the best outcome measure(s), on the basis of a sound clinimetric approach. More refined scales, such as the clinical version of the Total Neuropathy Score scale (TNSc), were tested and found as valid in this setting. The second step of our investigation was to apply outcome measures proposed by the CI-PeriNoms group, in longitudinal, prospective studies, on OXA-related neurotoxicity in colorectal (CRC) patients [4] , thus, obtaining more punctual data on incidence and severity of neurotoxicity in this specific population.
As the authors suggested further prospective, randomized trials are warranted to confirm the efficacy of Ca/Mg infusions or any other agent in OXA-related neurotoxicity. Efforts in this regard are quite needed in Oncology every-day practice, since OXA neurotoxicity is able to impact negatively on the quality of life in a population of long-survival patients, as large as CRC ones. In particular, acute toxicity, that might appear only a transient minor disturb, must not be overlooked; in fact, pronounced acute phenomena might be predictive of the development of a disabling chronic/cumulative neuropathy [5] .
We recommend that future experimental studies take into account the use of evidence-based, valid tools such as TNSc, as well as introduce reliable patient reported outcome measures to capture patients' perspective of CIPN and of neuroprotectants. 
